Asset overview
Program snapshot
Target: BCMA
Cell type: NK_CELL
Indications: Multiple Myeloma
Sponsor: RenJi Hospital
Institution: RenJi Hospital
Car Nk
ACT-001 CAR-NK cell
ACT-001 CAR-NK cell is flagged as a platform signal because it has an active early-phase oncology cell-therapy trial at RenJi Hospital, with a possible patent signal linked through modality_match. Manual review is still required.
Clinical evidence
Trial footprint
Phase: Na
Status: Not Yet Recruiting
Trial count: 1
Active trials: 0
First posted: September 19, 2024
Last updated: September 19, 2024
Signal summary
IP and BD posture
IP signal: Possible
BD label: Platform Signal
Confidence: Medium
Manual review required: Yes
Scores
Deterministic scoring
Clinical translation1
IP linkage3
Licensing clarity3
Strategic interest3
Source
Public trial record
Review the underlying ClinicalTrials.gov record and treat Treelip output as a prioritization layer, not a final diligence conclusion.
NCT IDs: NCT06594211